サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：がんにおけるフローサイトメトリー市場- 世界の産業規模、シェア、動向、機会、2017年～2027年予測
市場調査レポート
商品コード
1303138

がんにおけるフローサイトメトリー市場- 世界の産業規模、シェア、動向、機会、2017年～2027年予測

Flow Cytometry in Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technology, By Indication, By Application, By End User, By company and By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 114 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

がんにおけるフローサイトメトリー市場- 世界の産業規模、シェア、動向、機会、2017年～2027年予測
出版日: 2023年07月01日
発行: TechSci Research
ページ情報: 英文 114 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のがんにおけるフローサイトメトリー市場は、2023～2027年の予測期間中に目覚ましい成長を遂げると予測されています。

主な要因としては、がんの発生件数の増加、フローサイトメトリー分野の技術進化、精密医療やテーラーメイド治療に対する消費者の意識の高まりなどが市場の成長を後押ししています。フローサイトメトリーは、生物物理学的およびレーザーベースの分析技術であり、一般にレーザービームの助けを借りて液体中に浮遊する細胞またはミセルの評価に使用されます。この技術により、細胞の種類を細分化し、プローブを用いて疾患の残存レベルを特定することが容易になり、患者に対する効果的な治療計画を立てることができます。市場の成長を支えるその他の要因としては、がん診断分野における急速な開拓、研究開発活動の活発化、血液悪性腫瘍に対する資金注入の増加、フローサイトメトリー機器の採用増加、がんに関連する症例数の急激な増加、世界人口の増加、無機的成長戦略の採用増加、慢性疾患の出現が挙げられます。

がんおよび血液悪性腫瘍の有病率の上昇

フローサイトメトリーはがんの診断と最小残留レベルの検出に使用されます。肺がん、乳がん、胃がん、皮膚がん、咽頭がん、その他の血液関連がんなど、がん罹患率の増加が市場の成長を増大させています。WHOによると、2020年には、がんが顕著な死因となり、世界全体で約1,000万人、死亡者の約6人に1人が死亡すると報告されています。最も一般的ながんは、肺がん、結腸・直腸がん、乳がん、前立腺がんです。また、白血病、リンパ腫、骨髄腫などの血液学的悪性腫瘍に罹患する人が急増しており、その診断と残渣検出のためにフローサイトメトリーが必要とされています。米国がん協会によると、米国では約3分に1人が白血病、リンパ腫、骨髄腫と診断されています。

オーダーメイド治療と精密医療に対する消費者の意識の高まり

精密医療とオーダーメイド治療に対する消費者の意識の高まりが、市場の成長を後押ししています。テーラーメイド治療と精密医療に関連する利点について、人々は医師から教育を受けています。精密医療は様々ながんを治療する計り知れない大きな可能性を秘めており、市場の成長を後押ししています。さらに、人々の意識を高めるための政府による様々な取り組みが市場の成長を促進しています。例えば、2015年には米国でプレシジョン・メディシン・イニシアチブ（PMI）が開始されました。これは、医療提供における「画一的な」アプローチから脱却し、遺伝子、ライフスタイル、生物学など、人々固有の個性に合わせた治療や予防アプローチを用いるためのイニシアチブです。

市場成長を支えるサイトメトリー機器の技術開拓

操作性の容易さ、ワークフローの改善、迅速なデータ読み取りを提供する先進的なフローサイトメトリー製品の開発に主要企業が重点を置くようになっています。サイトメトリー機器の急速な発展により、治療実施やがん診断のモニタリングのためのフローサイトメーターの採用が急増しており、市場の成長を後押ししています。例えば、2018年、Merck KGaAは新しいCell Streamベンチトップフローサイトメトリーシステムを発売しました。これは、検出にカメラを使用する圧縮、カスタマイズ可能なフローサイトメーターです。この発売により、同社はフローサイトメーターの製品ラインを拡大しました。

利用可能なカスタマイズ

TechSciリサーチは、所定の市場データを用いて、企業の特定のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 がんにおけるフローサイトメトリーの世界市場に対するCOVID-19の影響

第5章 顧客の声

第6章 がんにおけるフローサイトメトリーの世界市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 適応症別
    • アプリケーション別
    • エンドユーザー別
    • 地域別
    • 企業別
  • 市場マップ

第7章 北米のがんにおけるフローサイトメトリー市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 適応症別
    • 用途別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州のがんにおけるフローサイトメトリー市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 適応症別
    • 用途別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋地域のがんにおけるフローサイトメトリー市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 適応症別
    • 用途別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米のがんにおけるフローサイトメトリー市場の展望

  • 市場規模および予測
    • 金額ベース
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 適応症別
    • 用途別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカのがんにおけるフローサイトメトリー市場の展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 適応症別
    • 用途別
    • エンドユーザー別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • トルコ
    • エジプト

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

第14章 競合情勢

  • Agilent Technologies, Inc.
  • Apogee Flow Systems Ltd.
  • Becton, Dickinson and Company
  • bioAffinity Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Cytognos, S.L.
  • Danaher Corporation
  • Miltenyi Biotec B.V. & Co. KG
  • Laboratory Corporation of America Holdings

第15章 戦略的提言

目次
Product Code: 13126

The global flow cytometry in the oncology market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing occurrences of cancer, technological evolution in the field of flow cytometry, and rising consumer awareness for precision medicine and tailored therapy are fueling the growth of the market. Flow cytometry is a biophysical and laser-based analytical technology that is used in the evaluation of cells or micelles that are generally suspended in a fluid with the help of a laser beam. This technique facilitates subclassifying cell types and identifying residual levels of disease using probes to develop an effective treatment plan for the patient. The other factors supporting the market's growth are rapid developments in the field of cancer diagnostics, rise in R&D activities, increasing fund infusions for hematological malignancies, rising adoption of flow cytometry instruments, the exponential rise in the number of cases associated with cancer, rise in world population base, growing adoption of inorganic growth strategies, and increasing emergence of chronic diseases.

Rising Prevalence of Cancer & Hematological Malignancies

Flow cytometry is used to diagnose cancer and detect minimal residue levels. Growing incidences of cancer, such as lung, breast, stomach, skin, throat, and other blood-related cancers, are augmenting the growth of the market. According to WHO, in 2020, cancer is a prominent cause of death, reporting nearly 10 million deaths globally, or nearly one in six deaths. The most common cancers are lung, colon and rectum, breast, and prostate cancers. Also, there is a surge in the number of people suffering from hematological malignancies such as leukemia, lymphoma, and myeloma, which need flow cytometry for the diagnosis and detection of residue. According to the American Cancer Society, in the United States, around every 3 minutes, a person is diagnosed with leukemia, lymphoma, and myeloma.

Growing Consumer Awareness for Tailored Therapy and Precision Medicines

The rising consumer awareness of precision medicine and tailored therapy is bolstering the growth of the market. People are being educated by doctors about the benefits associated with tailored therapy and precision medicine. Precision medicine has invaluable and enormous potential to cure various cancers, thus augmenting the growth of the market. Furthermore, various initiatives by the governments to raise awareness among people are facilitating the growth of the market. For instance, in 2015, The Precision Medicine Initiative (PMI) was launched in the US, an initiative to move away from the "one-size-fits-all" approach to health care delivery and to use tailor treatment and prevention approaches to people's unique individualities, including gene, lifestyle, and biology.

Technological Developments in Cytometry Instruments to Support Market Growth

Rising emphasis of key players on developing advanced flow cytometry products that offer ease in operability, improved workflows, and quick data reading. Owing to the rapid developments in cytometry instruments, the adoption of flow cytometers for therapeutic conducting and monitoring cancer diagnosis is surging, which propels the growth of the market. For instance, in 2018, Merck KGaA launched its new Cell Stream benchtop flow cytometry system, which is a compressed, customizable flow cytometer that uses a camera for detection. With this launch, the company has extended its product line in flow cytometers.

Market Segmentation

The global flow cytometry in the oncology market is segmented into component, technology, indication, application, end user, and company. Based on components, the market is divided into assays & kits, instruments, reagents & consumables, and software. Based on technology, the market is divided into cell-based and bead-based. Based on indication, the market is divided into hematological malignancies and solid tumors. Based on application, the market is divided into translational research and clinical applications. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of cancer and rising advancements in technology in the country.

Market Players

Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, bioAffinity Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytognos, S.L., Danaher Corporation, Miltenyi Biotec BV & Co. KG, and Laboratory Corporation of America Holdings are some of the leading companies operating in the market.

Report Scope

In this report, global flow cytometry in the oncology market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Flow Cytometry in Oncology Market, By Component:

  • Assays & Kits
  • Instruments
  • Reagents & Consumables
  • Software

Flow Cytometry in Oncology Market, By Technology:

  • Cell-Based
  • Bead Based

Flow Cytometry in Oncology Market, By Indication:

  • Hematological Malignancies
  • Solid Tumors

Flow Cytometry in Oncology Market, By Application:

  • Translational Research
  • Clinical Applications

Flow Cytometry in Oncology Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutions
  • Others

Flow Cytometry in Oncology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Flow Cytometry in Oncology Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Flow Cytometry in Oncology Market

5. Voice of Customer

6. Global Flow Cytometry in Oncology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Assays & Kits, Instruments, Reagents & Consumables, Software)
    • 6.2.2. By Technology (Cell Based v/s Bead Based)
    • 6.2.3. By Indication (Hematological Malignancies v/s Solid Tumors)
    • 6.2.4. By Application (Translational Research v/s Clinical Applications)
    • 6.2.5. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 6.2.6. By Region
    • 6.2.7. By Company (2021)
  • 6.3. Market Map

7. North America Flow Cytometry in Oncology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Technology
    • 7.2.3. By Indication
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Flow Cytometry in Oncology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Indication
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. Canada Flow Cytometry in Oncology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Indication
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. Mexico Flow Cytometry in Oncology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Indication
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User

8. Europe Flow Cytometry in Oncology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Technology
    • 8.2.3. By Indication
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Flow Cytometry in Oncology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Indication
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Germany Flow Cytometry in Oncology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Indication
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. United Kingdom Flow Cytometry in Oncology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Indication
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. Italy Flow Cytometry in Oncology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Indication
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Spain Flow Cytometry in Oncology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Indication
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Asia-Pacific Flow Cytometry in Oncology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Technology
    • 9.2.3. By Indication
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Flow Cytometry in Oncology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Indication
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. India Flow Cytometry in Oncology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Indication
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Japan Flow Cytometry in Oncology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Indication
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User
    • 9.3.4. South Korea Flow Cytometry in Oncology Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technology
        • 9.3.4.2.3. By Indication
        • 9.3.4.2.4. By Application
        • 9.3.4.2.5. By End User
    • 9.3.5. Australia Flow Cytometry in Oncology Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technology
        • 9.3.5.2.3. By Indication
        • 9.3.5.2.4. By Application
        • 9.3.5.2.5. By End User

10. South America Flow Cytometry in Oncology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Technology
    • 10.2.3. By Indication
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Flow Cytometry in Oncology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Indication
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Argentina Flow Cytometry in Oncology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Indication
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Colombia Flow Cytometry in Oncology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Indication
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Middle East and Africa Flow Cytometry in Oncology Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component
    • 11.2.2. By Technology
    • 11.2.3. By Indication
    • 11.2.4. By Application
    • 11.2.5. By End User
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Flow Cytometry in Oncology Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technology
        • 11.3.1.2.3. By Indication
        • 11.3.1.2.4. By Application
        • 11.3.1.2.5. By End User
    • 11.3.2. Saudi Arabia Flow Cytometry in Oncology Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technology
        • 11.3.2.2.3. By Indication
        • 11.3.2.2.4. By Application
        • 11.3.2.2.5. By End User
    • 11.3.3. UAE Flow Cytometry in Oncology Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technology
        • 11.3.3.2.3. By Indication
        • 11.3.3.2.4. By Application
        • 11.3.3.2.5. By End User
    • 11.3.4. Turkey Flow Cytometry in Oncology Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Component
        • 11.3.4.2.2. By Technology
        • 11.3.4.2.3. By Indication
        • 11.3.4.2.4. By Application
        • 11.3.4.2.5. By End User
    • 11.3.5. Egypt Flow Cytometry in Oncology Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Component
        • 11.3.5.2.2. By Technology
        • 11.3.5.2.3. By Indication
        • 11.3.5.2.4. By Application
        • 11.3.5.2.5. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Agilent Technologies, Inc.
  • 14.2. Apogee Flow Systems Ltd.
  • 14.3. Becton, Dickinson and Company
  • 14.4. bioAffinity Technologies, Inc.
  • 14.5. Bio-Rad Laboratories, Inc.
  • 14.6. Bio-Techne Corporation
  • 14.7. Cytognos, S.L.
  • 14.8. Danaher Corporation
  • 14.9. Miltenyi Biotec B.V. & Co. KG
  • 14.10. Laboratory Corporation of America Holdings

15. Strategic Recommendations